RBC Lifts PT on Aerie Pharma (AERI) to $55 Following Roclatan Phase 3 Results
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
RBC Capital boosts its price target on Outperform-rated Aerie Pharmaceuticals (Nasdaq: AERI) from $51 to $55 after the company announced positive Roclatan phase 3 data.
The firm commented,
The second Phase 3 is similar in design so it should work as well making Roclatan approvable, a standard of care, and blockbuster drug for glaucoma. Rhopressa gets approved in 2017 and Roclatan in 2018. Given the rarity of new mechanisms targeting glaucoma, AERI could be successful independently or as a likely takeout.
We are raising our price target to $55 to reflect greater confidence in AERI’s anti-glaucoma franchise to both become a blockbuster and eligible for a take-out. First positive Phase 3 for Roclatan significantly de-risks the program and de-risking should continue with each future readout for Rhopressa and Roclatan.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Raises Price Target on NeuroDerm (NDRM) to $30 After Meeting with FDA
- Oppenheimer Assumes Kempharm (KMPH) at Outperform
- MKM Partners Raises Price Target on Arista Networks (ANET) Following U.S. Customs and Border Protection Approval
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!